Journal
CLINICAL CHEMISTRY
Volume 63, Issue 4, Pages 816-822Publisher
AMER ASSOC CLINICAL CHEMISTRY
DOI: 10.1373/clinchem.2016.257444
Keywords
-
Categories
Funding
- Affymetrix, Inc.
- Burroughs Wellcome Trust
- NCI [K12CA087723, R01CA163705]
- Warshaw Institute for Pancreatic Cancer Research
- Verville Family Pancreatic Cancer Research Fund
- Burroughs Wellcome Fund
- NIGMS [R01 GM103999]
- Systems Biology of Retrotransposition NIGMS [P50GM107632]
Ask authors/readers for more resources
BACKGROUND: A large portion of intronic and intergenic space in our genome consists of repeated sequences. One of the most prevalent is the long interspersed element-1 (LINE-1, L1) mobile DNA. LINE-1 is rightly receiving increasing interest as a cancer biomarker. CONTENT: Intact LINE-1 elements are self-propagating. They code for RNA and proteins that function to make more copies of the genomic element. Our current understanding is that this process is repressed in most normal cells, but that LINE-1 expression is a hallmark of many types of malignancy. Here, we will consider features of cancer cells when cellular defense mechanisms repressing LINE-1 go awry. We will review evidence that genomic LINE-1 methylation, LINE-1 encoded RNAs, and LINE-1 ORF 1p (open reading frame 1 protein) may be useful in cancer diagnosis. SUMMARY: The repetitive and variable nature of LINE-1 DNA sequences poses unique challenges to studying them, but recent advances in reagents and next generation sequencing present opportunities to characterize LINE-1 expression and activity in cancers and to identify clinical applications. (C) 2016 American Association for Clinical Chemistry
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available